Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 243
- Registration Number
- NCT03206749
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Lotus Clinical Research, Pasadena, California, United States
A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 98
- Registration Number
- NCT03150719
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 57
- Registration Number
- NCT03125395
- Locations
- 🇺🇸
Children's Hospital of the King's Daughters, Norfolk, Virginia, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 38
- Registration Number
- NCT03068312
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT03061331
- Locations
- 🇳🇱
HagaZiekenhuis, Den Haag, Netherlands
🇳🇱University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis, Heidelberglaan, Netherlands
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 163
- Registration Number
- NCT03029455
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 11
- Registration Number
- NCT02971839
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Stanford Hospital, Palo Alto, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 83
- Registration Number
- NCT02953314
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 74
- Registration Number
- NCT02951182
- Locations
- 🇺🇸
St. Luke's CF Center of Idaho, Boise, Idaho, United States
🇺🇸The University of Texas Southwestern Center, Dallas, Texas, United States
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 80
- Registration Number
- NCT02951195